Other studies have shown that peptidoglycans can activate TLR2 and induce peripheral blood mononuclear cells in SS patients to produce IL-17 and IL-23 via the IL-6, STAT3, and NF–kB signaling pathways [80]. Here, STAT3 is linked to synovial sarcoma.